Table 1 The characteristics of the two study populations
CSi ( N =23 632) | Horizon ( N =3347) | |||||||
|---|---|---|---|---|---|---|---|---|
CSi-attenders ( n =4865) | GP-attenders ( n =4291) | Non-responders ( n =14 476) | GP-taken sample ( n =3347) | |||||
Mean age (years; 95% CI) | 47.1 | (46.8–47.5) | 40.3 | (40.0–40.6) | 47.6 | (47.4–47.8) | 40.6 | (40.3–41.0) |
Age group (years) | ||||||||
27–29 | 385 | 7.9% | 588 | 13.7% | 1318 | 9.1% | 478 | 14.3% |
30–39 | 1092 | 22.4% | 1657 | 38.6% | 2962 | 20.5% | 1295 | 38.7% |
40–49 | 1215 | 25.0% | 1311 | 30.6% | 3107 | 21.5% | 897 | 26.8% |
50–59 | 1275 | 26.2% | 514 | 12.0% | 4099 | 28.3% | 462 | 13.8% |
60–65 | 898 | 18.5% | 221 | 5.1% | 2990 | 20.7% | 215 | 6.4% |
Total | 4865 | 100.0% | 4291 | 100.0% | 14 476 | 100.0% | 3347 | 100.0% |
Screening historya | ||||||||
Long-term unscreened | 1621 | 39.9% | 927 | 30.8% | 7540 | 64.0% | 133 | 5.8% |
Intermittently screened | 2440 | 60.1% | 2083 | 69.2% | 4243 | 36.0% | 2158 | 94.2% |
Total | 4061 | 100.0% | 3010 | 100.0% | 11 783 | 100.0% | 2291 | 100.0% |
Histology (regardless of the HPV test result) | ||||||||
Normal | 134 | 47.3% | 188 | 57.8% | 47 | 78.3% | 206 | 56.3% |
CIN1 | 45 | 15.9% | 30 | 9.2% | 1 | 1.7% | 44 | 12.0% |
CIN2 | 22 | 7.8% | 23 | 7.1% | 0 | 0.0% | 24 | 6.6% |
CIN3 | 76 | 26.9% | 76 | 23.4% | 6 | 10.0% | 61 | 16.7% |
Cervical cancer | 5 | 1.8% | 7 | 2.2% | 6 | 10.0% | 1 | 0.3% |
Inadequate material | 1 | 0.4% | 1 | 0.3% | 0 | 0.0% | 30 | 8.2% |
Total | 283 | 100.0% | 325 | 100.0% | 60 | 100.0% | 366 | 100.0% |
⩾CIN2 detection (regardless of the HPV test result) | ||||||||
<CIN2 | 179 | 63.5% | 218 | 67.3% | 48 | 80.0% | 250 | 74.4% |
⩾CIN2 (positive predictive value) | 103 | 36.5% | 106 | 32.7% | 12 | 20.0% | 86 | 25.6% |
Total | 282 | 100.0% | 324 | 100.0% | 60 | 100.0% | 336 | 100.0% |
Positive predictive value of ⩾CIN2 detection compared with Horizon | P<0.01 | P=0.02 | P=0.93 | Reference | ||||
